All News

    Anemia Management in Myelofibrosis: Survival and Quality of Life

    October 25th 2025, 6:00pm

    Article

    Dr. Francesca Palandri discusses anemia in myelofibrosis, its impact on survival and quality of life, and the potential of Ojjaara for patients.

    Simple Ways for Patients With Cancer to Start Exercising

    October 25th 2025, 2:00pm

    Article

    Exercise, as an expert explained to CURE, can have a significant positive impact on long-term outcomes for patients with cancer.

    Finding Credible Voices in the Lynch Syndrome Community

    October 24th 2025, 9:00pm

    Article

    When you’re living with a hereditary cancer syndrome, where you get your information matters just as much as the information itself.

    Understanding Your Stage 2 Lymphoma Diagnosis

    October 24th 2025, 8:00pm

    Article

    Stage 2 lymphoma is treatable. Diagnosis and treatment depend on subtype, but most patients achieve excellent outcomes with modern therapies.

    FDA Approves Revuforj for R/R NPM1-Mutant AML

    October 24th 2025, 6:12pm

    Article

    The FDA has approved Revuforj for relapsed or refractory acute myeloid leukemia with an NPM1 mutation.

    How Does FDA-Approved Blenrep Treat Multiple Myeloma?

    October 24th 2025, 5:00pm

    Video

    CURE spoke with Dr. Surbhi Sidana about the recently approved antibody-drug conjugate Blenrep for multiple myeloma.

    Insights on Fertility and Survivorship in Hairy Cell Leukemia

    October 24th 2025, 4:00pm

    Video

    Dr. Alessandro Gozzetti highlights fertility and reproductive health as often overlooked but vital aspects of survivorship in hairy cell leukemia.

    Rituxan Combinations Show Longer Remissions in Hairy Cell Leukemia

    October 24th 2025, 3:00pm

    Video

    Combining Rituxan with Mavenclad or Zelboraf upfront can extend remissions safely and should become standard first-line therapy for hairy cell leukemia.

    FDA Fast Tracks MT-125 for Glioblastoma

    October 24th 2025, 1:29pm

    Article

    The FDA has granted fast track designation to MT-125 for the treatment of patients with glioblastoma.

    FDA Approves Blenrep Plus Velcade/Dexamethasone For R/R Multiple Myeloma

    October 23rd 2025, 10:18pm

    Article

    The FDA approved Blenrep with Velcade and dexamethasone for relapsed or refractory multiple myeloma.